

Prof. Dr. med. Wilko Weichert,

Born: 22.09.1970

Institute of Pathology, Trogerstr. 18, 81675 München
Technical University Munich
Phone: +49 89 4140 4161
Email: wilko.weichert@tum.de
Homepage: www.path.med.tum.de



Current Position and Professional Career

- 2015-** *Full Professor for Anatomical and Surgical Pathology and Chairman, Institute of Pathology, Technical University Munich*
- 2012-2015 Head of Molecular Pathology, National Center for Tumor Diseases (NCT) of the German Cancer Research Center (dkfz), Heidelberg
- 2010-2015 Full Professor for Pathology and Deputy Director Institute of Pathology, Ruprecht-Karls-University, Heidelberg
- 2007-2010 Assistant Professor of Pathology (Privatdozent) at the Institute of Pathology, Charité
- 2001-2007 Resident at the Institute of Pathology, Charité University Medicine, Berlin

Research Focus and Research Experience

Translational tumor research with a focus on tissue based morphomolecular pathology for the discovery and clinical implementation of novel diagnostic and predictive biomarkers guiding innovative new therapeutic concepts: Expert in gastrointestinal and pancreatic tumors.

Positions, Grants, Scientific Awards and Memberships

- 2019- present Member of the Board of Directors of the Bavarian Cancer Research Center (BZKF)
- 2019- present Spokesperson for the Munich Site as well as Member of the Board of Directors of the DKTK
- 2019- present Member of the Scientific Advisory Council of the Wilhelm-Sander-Stiftung
- 2017- present Coordinator for Molecular Diagnostics of the German Cancer Consortium (DKTK)
- 2016- present Elected Member (since 2020 speaker) of the Expert Council on Cancer of the German Research Foundation (DFG)
- 2016- present Federally appointed Expert Advisor for the European Medical Agency (EMA)
- 2015- present Member of the Board of Directors of the German Society of Pathology

Currently running third party funding from the DFG (SFB 824, 1321, 1335), EU (BIGPICTURE, ESPACE), BMBF/DKTK (CLINSPECT-M, MEMORI, SubPAN, EPIC-G8, INFORM/MASTER-pro, MTB-Alliance), German Cancer Aid (IntegrateTN), Bav. StM (Pathoscan) and Industry cooperations (AstraZeneca, MSD, BMS, Roche)

Publications

>460 peer reviewed publications (PubMed), several book chapters, 15.904 citations, H-Index 64, (WoS).

Selection

1. Jesinghaus, M. ... **Weichert, W.** Morphology matters: A critical reappraisal of the clinical relevance of morphologic criteria from the 2019 WHO classification in a large colorectal cancer cohort comprising 1004 cases. In press (2021).
2. Walter, W., ..., **Weichert, W.** Next-generation diagnostics for precision oncology: preanalytical considerations, technical challenges, and available technologies. *Semin Cancer Biol.* In press (2021).
3. Muckenhuber, A., ..., Weichert, W. Pancreatic Ductal Adenocarcinoma Subtyping using the Biomarkers Hepatocyte Nuclear Factor-1A and Cytokeratin-81 Correlates with Outcome and Treatment Response. *Clinical Cancer Research* 24, 351 (2018).
4. Warth, A., ..., **Weichert, W.** The novel histologic International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification system of lung adenocarcinoma is a stage-independent predictor of survival *J Clin Oncol* 30, 1438-46 (2012).
5. **Weichert, W.**, ..., Röcken, C. Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis. *The Lancet Oncology* 9, 139-148 (2008).